PD-L1
low
< median
expression
(n = 355)
PD-L1
high
≥ median
expression
(n = 356)
OS HR
0.68
OS HR
0.74
Atezolizumab Docetaxel
8.7
11.3
12.7
16.3
Biomarker
evaluable
(n = 711)
9.5
14.2
PD-L1
gene expression
Median OS, mo
Overall survival by PD-L1 tumor gene expression or
IHC
• Improved OS for atezolizumab vs docetaxel
observed in patients with high and low
PD-L1
gene expression
b
•
PD-L1
gene expression is highly correlated
with PD-L1 IHC
1
• OS HR in low
PD-L1
gene expression
subgroup (50% prevalence) similar to that
seen in the PD-L1 IHC TC0 and IC0
population (45% prevalence)
2
• Two different PD-L1 biomarker assessments
(IHC and gene expression) both demonstrate
broad OS benefit of atezolizumab, including
patients with low/no PD-L1 expression
OS HR
0.74
OS HR
0.75
TC0 and
IC0
(n = 379)
TC1/2/3 or
IC1/2/3
a
(n = 463)
Atezolizumab Docetaxel
8.9
10.3
12.6
15.7
ITT
a
(n = 850)
9.6
13.8
PD-L1 IHC
Median OS, mo
a
Stratified HR for ITT and TC1/2/3 or IC1/2/3, Unstratified HR for TC0 and IC0.
b
Tumor tissue assessed by Fluidigm gene-expression platform
PD-L1 ‘low’ defined as expression < median in OAK population, PD-L1 ‘high’ defined as ≥ median expression.
TC, tumor cells; IC, tumor-infiltrating immune cells; IHC, immunohistochemistry.
1. Williams et al. ESMO 2016 (1171P); 2. Barlesi et al. ESMO 2016 LBA44
OAK STUDY
